{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:16:48Z","timestamp":1788376608567,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04175-5","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:00:28Z","timestamp":1778572828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-Ro-52 antibody is a risk factor for recurrence in interstitial lung disease with positive anti-aminoacyl tRNA synthetase antibody: a single-center, retrospective observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hiroshi","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoju","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Hamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"4175_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91\u20139. https:\/\/doi.org\/10.1016\/j.rmed.2016.10.019.","journal-title":"Respir Med"},{"key":"4175_CR2","doi-asserted-by":"publisher","first-page":"e0120313","DOI":"10.1371\/journal.pone.0120313","volume":"10","author":"H Hozumi","year":"2015","unstructured":"Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS ONE. 2015;10:e0120313. https:\/\/doi.org\/10.1371\/journal.pone.0120313.","journal-title":"PLoS ONE"},{"key":"4175_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403\u20137. https:\/\/doi.org\/10.1056\/NEJM197502202920807.","journal-title":"N Engl J Med"},{"key":"4175_CR4","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138:1464\u201374. https:\/\/doi.org\/10.1378\/chest.10-0180.","journal-title":"Chest"},{"key":"4175_CR5","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","volume":"57","author":"S Sato","year":"2018","unstructured":"Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatol (Oxf Engl). 2018;57:1212\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/key060.","journal-title":"Rheumatol (Oxf Engl)"},{"key":"4175_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rmed.2017.04.007","volume":"127","author":"K Tanizawa","year":"2017","unstructured":"Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2017;127:57\u201364. https:\/\/doi.org\/10.1016\/j.rmed.2017.04.007.","journal-title":"Respir Med"},{"key":"4175_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000488358","volume":"96","author":"H Yamakawa","year":"2018","unstructured":"Yamakawa H, Hagiwara E, Kitamura H, Iwasawa T, Otoshi R, Aiko N, et al. Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies. Respiration. 2018;96:210\u201321. https:\/\/doi.org\/10.1159\/000488358.","journal-title":"Respiration"},{"key":"4175_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","volume":"58","author":"R Takei","year":"2020","unstructured":"Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, et al. Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease. Respir Investig. 2020;58:83\u201390. https:\/\/doi.org\/10.1016\/j.resinv.2019.10.004.","journal-title":"Respir Investig"},{"key":"4175_CR9","doi-asserted-by":"publisher","first-page":"103013","DOI":"10.1016\/j.autrev.2021.103013","volume":"21","author":"P Decker","year":"2022","unstructured":"Decker P, Moulinet T, Pontille F, Cravat M, De Carvalho Bittencourt M, Jaussaud R. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun Rev. 2022;21:103013. https:\/\/doi.org\/10.1016\/j.autrev.2021.103013.","journal-title":"Autoimmun Rev"},{"key":"4175_CR10","doi-asserted-by":"publisher","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","volume":"172","author":"X Xing","year":"2020","unstructured":"Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med. 2020;172:106134. https:\/\/doi.org\/10.1016\/j.rmed.2020.106134.","journal-title":"Respir Med"},{"key":"4175_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626\u201336. https:\/\/doi.org\/10.1067\/mjd.2002.120621.","journal-title":"J Am Acad Dermatol"},{"key":"4175_CR12","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","volume":"59","author":"SL Tansley","year":"2020","unstructured":"Tansley SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology (Oxford). 2020;59:2109\u201314.","journal-title":"Rheumatology (Oxford)"},{"key":"4175_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","volume":"433","author":"I Cavazzana","year":"2016","unstructured":"Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N, et al. Testing for myositis specific autoantibodies: comparison between line blot and Immunoprecipitation assays in 57 myositis Sera. J Immunol Methods. 2016;433:1\u20135.","journal-title":"J Immunol Methods"},{"key":"4175_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","volume":"85","author":"Y Waseda","year":"2016","unstructured":"Waseda Y, Johkoh T, Egashira R, Sumikawa H, Saeki K, Watanabe S, et al. Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol. 2016;85:1421\u20136.","journal-title":"Eur J Radiol"},{"key":"4175_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1183\/09031936.06.00038806","volume":"28","author":"T Suda","year":"2006","unstructured":"Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28:1005\u201312. https:\/\/doi.org\/10.1183\/09031936.06.00038806.","journal-title":"Eur Respir J"},{"key":"4175_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319\u201338. https:\/\/doi.org\/10.1183\/09031936.05.00034805.","journal-title":"Eur Respir J"},{"key":"4175_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1183\/09031936.05.00034905","volume":"26","author":"N Macintyre","year":"2005","unstructured":"Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720\u201335. https:\/\/doi.org\/10.1183\/09031936.05.00034905.","journal-title":"Eur Respir J"},{"key":"4175_CR18","doi-asserted-by":"publisher","first-page":"106741","DOI":"10.1016\/j.rmed.2022.106741","volume":"193","author":"K Yamaguchi","year":"2022","unstructured":"Yamaguchi K, Fukushima Y, Yamaguchi A, Itai M, Shin Y, Uno S, et al. Influence of obesity in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2022;193:106741. https:\/\/doi.org\/10.1016\/j.rmed.2022.106741.","journal-title":"Respir Med"},{"key":"4175_CR19","doi-asserted-by":"publisher","first-page":"e232558","DOI":"10.1148\/radiol.232558","volume":"310","author":"AA Bankier","year":"2024","unstructured":"Bankier AA, MacMahon H, Colby T, Gevenois PA, Goo JM, Leung ANC, et al. Fleischner society: glossary of terms for thoracic imaging. Radiology. 2024;310:e232558. https:\/\/doi.org\/10.1148\/radiol.232558.","journal-title":"Radiology"},{"key":"4175_CR20","doi-asserted-by":"publisher","first-page":"1407633","DOI":"10.3389\/fimmu.2024.1407633","volume":"15","author":"S Matsuda","year":"2024","unstructured":"Matsuda S, Kotani T, Oe K, Okazaki A, Kiboshi T, Suzuka T, et al. Poor prognostic factors for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies after combination therapy. Front Immunol. 2024;15:1407633.","journal-title":"Front Immunol"},{"issue":"3","key":"4175_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","volume":"37","author":"M Nakazawa","year":"2018","unstructured":"Nakazawa M, Kaneko Y, Takeuchi T. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study. Clin Rheumatol. 2018;37(3):765\u201371.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"4175_CR22","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","volume":"163","author":"RW Hallowell","year":"2023","unstructured":"Hallowell RW, Danoff SK. Diagnosis and management of Myositis-Associated lung disease. Chest. 2023;163(6):1476\u201391.","journal-title":"Chest"},{"key":"4175_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jcla.21522","volume":"26","author":"SA Lee","year":"2012","unstructured":"Lee SA, Kahng J, Kim Y, Park YJ, Han K, Kwok SK, et al. Comparative study of immunofluorescent antinuclear antibody test and line immunoassay detecting 15 specific autoantibodies in patients with systemic rheumatic disease. J Clin Lab Anal. 2012;26:307\u201314. https:\/\/doi.org\/10.1002\/jcla.21522.","journal-title":"J Clin Lab Anal"},{"key":"4175_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/08916934.2012.732131","volume":"46","author":"A Men\u00e9ndez","year":"2013","unstructured":"Men\u00e9ndez A, G\u00f3mez J, Escanlar E, Caminal-Montero L, Mozo L. Clinical associations of anti-SSA\/Ro60 and anti-Ro52\/TRIM21 antibodies: diagnostic utility of their separate detection. Autoimmunity. 2013;46:32\u20139. https:\/\/doi.org\/10.3109\/08916934.2012.732131.","journal-title":"Autoimmunity"},{"key":"4175_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00296-010-1790-x","volume":"32","author":"JS Song","year":"2012","unstructured":"Song JS, Do JH, Lee SW. The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sj\u00f6gren\u2019s syndrome. Rheumatol Int. 2012;32:491\u20135. https:\/\/doi.org\/10.1007\/s00296-010-1790-x.","journal-title":"Rheumatol Int"},{"key":"4175_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","volume":"8","author":"J Schulte-Pelkum","year":"2009","unstructured":"Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro\/SS-A autoantibody system. Autoimmun Rev. 2009;8:632\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2009.02.010.","journal-title":"Autoimmun Rev"},{"key":"4175_CR27","doi-asserted-by":"publisher","first-page":"e32001","DOI":"10.1371\/journal.pone.0032001","volume":"7","author":"KH Ching","year":"2012","unstructured":"Ching KH, Burbelo PD, Tipton C, Wei C, Petri M, Sanz I, et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS ONE. 2012;7:e32001. https:\/\/doi.org\/10.1371\/journal.pone.0032001.","journal-title":"PLoS ONE"},{"key":"4175_CR28","first-page":"S131","volume":"33","author":"M Wodkowski","year":"2015","unstructured":"Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, et al. Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol. 2015;33:S131\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"4175_CR29","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/art.39316","volume":"67","author":"KA Patterson","year":"2015","unstructured":"Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, et al. Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis. Arthritis Rheumatol. 2015;67:3234\u201344. https:\/\/doi.org\/10.1002\/art.39316.","journal-title":"Arthritis Rheumatol"},{"key":"4175_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","volume":"55","author":"R Gunnarsson","year":"2016","unstructured":"Gunnarsson R, El-Hage F, Aal\u00f8kken TM, Reiseter S, Lund MB, Garen T, et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatol (Oxf Engl). 2016;55:103\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kev300.","journal-title":"Rheumatol (Oxf Engl)"},{"key":"4175_CR31","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/ar2276","volume":"9","author":"M Koenig","year":"2007","unstructured":"Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Sen\u00e9cal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78. https:\/\/doi.org\/10.1186\/ar2276.","journal-title":"Arthritis Res Ther"},{"key":"4175_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/cei.13211","volume":"194","author":"S Brauner","year":"2018","unstructured":"Brauner S, Ivanchenko M, Thorlacius GE, Ambrosi A, Wahren-Herlenius M. The Sj\u00f6gren\u2019s syndrome-associated autoantigen Ro52\/TRIM21 modulates follicular B cell homeostasis and Immunoglobulin production. Clin Exp Immunol. 2018;194:315\u201326. https:\/\/doi.org\/10.1111\/cei.13211.","journal-title":"Clin Exp Immunol"},{"key":"4175_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, et al. Clinical profiles and prognosis of patients with distinct anti-synthetase autoantibodies. J Rheumatol. 2017;44:1051\u20137. https:\/\/doi.org\/10.3899\/jrheum.161480.","journal-title":"J Rheumatol"},{"key":"4175_CR34","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1128\/MCB.01630-05","volume":"26","author":"A Sabile","year":"2006","unstructured":"Sabile A, Meyer AM, Wirbelauer C, Hess D, Kogel U, Scheffner M, et al. Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein. Mol Cell Biol. 2006;26:5994\u20136004. https:\/\/doi.org\/10.1128\/MCB.01630-05.","journal-title":"Mol Cell Biol"},{"key":"4175_CR35","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.bbrc.2011.12.010","volume":"417","author":"SN Jauharoh","year":"2012","unstructured":"Jauharoh SN, Saegusa J, Sugimoto T, Ardianto B, Kasagi S, Sugiyama D, et al. SS-A\/Ro52 promotes apoptosis by regulating Bcl-2 production. Biochem Biophys Res Commun. 2012;417:582\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2011.12.010.","journal-title":"Biochem Biophys Res Commun"},{"key":"4175_CR36","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","volume":"41","author":"I Marie","year":"2012","unstructured":"Marie I, Hatron PY, Dominique S, Ardianto B, Kasagi S, Sugiyama D, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2012;41:890\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.09.008.","journal-title":"Semin Arthritis Rheum"},{"key":"4175_CR37","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/ar3763","volume":"14","author":"M Hudson","year":"2012","unstructured":"Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, et al. Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012;14:R50. https:\/\/doi.org\/10.1186\/ar3763.","journal-title":"Arthritis Res Ther"},{"key":"4175_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/rheumatology\/kex077","volume":"57","author":"S Reiseter","year":"2018","unstructured":"Reiseter S, Gunnarsson R, Mogens Aal\u00f8kken T, Lund MB, Mynarek G, Corander J, et al. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatol (Oxf Engl). 2018;57:255\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/kex077.","journal-title":"Rheumatol (Oxf Engl)"},{"key":"4175_CR39","doi-asserted-by":"publisher","unstructured":"Imai R, Bermea RS, Zhao SH, Montesi SB, Singh A, Flashner BM, et al. Anti-Ro52 seropositive interstitial lung disease is associated with a higher risk for disease progression and mortality. Chest. 2025;S0012\u20133692. https:\/\/doi.org\/10.1016\/j.chest.2025.05.036. 25)00687-7.","DOI":"10.1016\/j.chest.2025.05.036"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04175-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:33:40Z","timestamp":1783395220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04175-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04175-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7374658\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Kurashiki Central Hospital, Ethics Committee for Clinical Research (approval number: No. 4315, February 9, 2024). The requirement for written informed consent was waived by the Institutional Review Board of Kurashiki Central Hospital, as the study involved a retrospective review of patient records. No questionnaire was used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}